In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CAR-T Cancer Drugs Front And Center At ARM Investor Day

Executive Summary

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

Advertisement

Related Content

Too Sick For CAR-T? Kite Reports Cerebral Edema Death
CAR T-Cells, Helping US Firms & An “Ambitious” Plan For Advanced Therapies In The EU
BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
RAT Race Begins: FDA Accepting Regenerative Advanced Therapy Designation Requests
Curative Regenerative Medicines: Preparing Health Care Systems For The Coming Wave
Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV005097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel